Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupSMHGF 95 Earnings Yield (Joel Greenblatt) % is 6.31% as of Dec. 2025, which is 11% above its 10-year median of 5.69. GuruFocus rates SMHGF with a GF Score™ of 95/100 and a GF Value™ of $1.37. Among 1,007 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 72.79% on this metric.
Simcere Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2025 was $4,749 Mil.
Simcere Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $278 Mil. Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 6.31%.
The historical rank and industry rank for Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SMHGF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.67 Med: 5.69 Max: 10.66
Current: 7.82
During the past 9 years, the highest Earnings Yield (Joel Greenblatt) of Simcere Pharmaceutical Group was 10.66%. The lowest was 2.67%. And the median was 5.69%.
SMHGF's Earnings Yield (Joel Greenblatt) % is ranked better than 72.79% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.25
vs SMHGF: 7.82
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Simcere Pharmaceutical Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 3.77%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Simcere Pharmaceutical Group (OTCPK:SMHGF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Simcere Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Related Terms
Simcere Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Chart
SMHGF vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % falls into.
Simcere Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Simcere Pharmaceutical Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 6.31% mean?
Simcere Pharmaceutical Group (SMHGF) has a Earnings Yield (Joel Greenblatt) % of 6.31% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Simcere Pharmaceutical Group and its competitors. This is 11% above median its historical median of 5.69. Over the past decade, Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % has ranged from 2.67 to 10.66. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #274 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 27.2%.
Is Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % too high?
Simcere Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % of 6.31% is 11% above median its 10-year median of 5.69. Over the past 10 years, this metric has ranged from a low of 2.67 to a high of 10.66. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.25. Simcere Pharmaceutical Group's value of 6.31% is 94.2% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #274 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #274 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.25. Simcere Pharmaceutical Group's value of 6.31% is 94.2% above this benchmark. Historically, Simcere Pharmaceutical Group's own Earnings Yield (Joel Greenblatt) % has ranged from 2.67 to 10.66 over the past decade. While the company's 10-year median is 5.69 vs. the industry median of 3.25, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.25, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % of 6.31% is 94.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % is 6.31%, which is 11% above median its own 10-year median of 5.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (SMHGF) has a current Earnings Yield (Joel Greenblatt) % of 6.31%. The stock's GF Value™ is $1.37, compared to a current price of $1.49 — trading 8.7% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 6.31%, which is 11% above median its 10-year median of 5.69 and 94.2% above the Drug Manufacturers industry median of 3.25. Simcere Pharmaceutical Group's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current Earnings Yield (Joel Greenblatt) % is 6.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.49 is trading 8.7% above its estimated GF Value™ of $1.37.
Key valuation signals for SMHGF:
Earnings Yield (Joel Greenblatt) %: 6.31% (11% above median its 10-year median of 5.69)
GF Value™: $1.37 vs. price of $1.49 (8.7% above fair value)
Industry Position: 94.2% above the Drug Manufacturers median (#274 of 1007)
No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
95GF Score
Get the complete analysis for SMHGF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMHGF has been successfully added to your 
